Lv5
1540 积分 2023-07-18 加入
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
25天前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
25天前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
30天前
已完结
Target Populations for Novel Triglyceride-Lowering Therapies
30天前
已完结
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities
30天前
已完结
Pharmacological treatment for metabolic dysfunction–associated steatotic liver disease and related disorders: Current and emerging therapeutic options
30天前
已完结
Development and validation of ELISA method for quantification of Q-1802 in serum and its application to pharmacokinetic study in ICR Mouse
1个月前
已完结
The role of cytokines in shaping the future of Cancer immunotherapy
1个月前
已完结
CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells
2个月前
已完结
Nanobody-engineered bispecific IL-18 mimetics drive antitumor immunity by engaging CD8+ T cell and evading IL-18BP in preclinical models
2个月前
已完结
皖公网安备34019202002308
